论文部分内容阅读
目的研究不同治疗方案对老年胶质母细胞瘤患者生存期的影响。方法采用单因素生存分析法,生存曲线的比较采用log-rank检验,多因素生存分析采用Cox回归模型,分析治疗方案、年龄、是否服用替莫唑胺、KPS评分、肿瘤部位、大小等因素对生存时间的影响。结果通过单因素生存分析,老年胶质母细胞瘤患者的生存期与其治疗方案(放疗、手术局部切除、手术全部切除)、年龄(≤75岁、>75岁)、是否服用替莫唑胺、KPS评分(<70分、70~90分、>90分)等因素有关(P<0.05);而生存期与肿瘤部位(额、颞、顶、枕叶)、大小(≤4 cm、>4 cm)无关(P>0.05)。多因素分析:治疗方案为手术全部切除、服用替莫唑胺、KPS评分越高(<70分、70~90分、>90分)等因素为老年胶质母细胞瘤患者的生存期保护因素(P<0.05);而年龄越大则表现为危险因素(P<0.05)。生存期与肿瘤部位(额、颞、顶、枕叶)、大小(≤4 cm、>4 cm)等因素的分析提示差异无统计学意义(P>0.05)。结论治疗方案为手术全部切除、服用替莫唑胺、KPS评分越高(<70分、70~90分、>90分)等因素为老年胶质母细胞瘤患者的生存期的保护因素;年龄越大则表现为危险因素。肿瘤大小及肿瘤部位对中位生存时间无明显影响。
Objective To study the effect of different treatment regimens on the survival of patients with glioblastoma. Methods Single-factor survival analysis was used to compare survival curves with log-rank test. Cox regression model was used to analyze the treatment regimen, age, whether to take temozolomide, KPS scores, tumor location, size and other factors on survival time influences. Results One-factor survival analysis showed that the survival of patients with glioblastoma was significantly lower than that of patients treated with temozolomide and KPS score (radiotherapy, partial excision and total resection), age (≤75 years,> 75 years old) <70, 70-90,> 90) (P <0.05). The survival time was not related to tumor size (frontal, temporal, top and occipital lobe), size (≤4 cm,> 4 cm) (P> 0.05). Multivariate analysis: The treatment regimen was totally surgically removed. The higher the KPS scores (<70, 70-90,> 90) were, the higher the KPS scores were (p < 0.05), while older age showed risk factors (P <0.05). There was no significant difference in survival and tumor location (frontal, temporal, apex, occipital lobe), size (≤4 cm,> 4 cm) and other factors (P> 0.05). Conclusions The treatment regimen is totally surgically removed. Taking temozolomide with higher KPS scores (<70, 70-90,> 90) is a protective factor for the survival of the elderly glioblastoma patients. The older the The performance of risk factors. Tumor size and tumor site had no significant effect on median survival time.